ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Antibiotics Firm Agrees To Go Private F
ScripA drug developer went public in the US for the first time in more than two months when MAIA Biotechnology, Inc. raised $10m from the sale of 2 million shares at $5 each on 27 July, taking advantage
ScripVenture capital investors are doubling down, placing new bets on drug developers even as the public markets are taking money off the table in the biopharmaceutical sector. For instance, Texas Medical
ScripStock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture